Catalyst Pharmaceuticals Newsroom

Catalyst Pharmaceuticals Analyst Ratings

BenzingaJun 6 10:24 ET

Catalyst Pharmaceuticals Analyst Ratings

BenzingaJun 3 06:28 ET

Catalyst Pharmaceuticals Analyst Ratings

BenzingaMay 10 08:12 ET

Catalyst Pharmaceuticals Analyst Ratings

BenzingaMar 27 07:37 ET

Catalyst Pharmaceuticals Analyst Ratings

BenzingaMar 22 14:00 ET

Cantor Fitzgerald Reiterates Overweight on Catalyst Pharmaceuticals, Maintains $34 Price Target

BenzingaMar 22 14:00 ET

Catalyst Pharmaceuticals Analyst Ratings

BenzingaMar 14 08:05 ET

Catalyst Pharmaceuticals Analyst Ratings

BenzingaMar 7 11:02 ET

BofA Securities Initiates Catalyst Pharmaceuticals With Buy Rating, Price Target Is $23

MT NewswiresMar 7 10:20 ET

Catalyst Pharmaceuticals Analyst Ratings

BenzingaMar 1 06:36 ET

Catalyst Pharmaceuticals Analyst Ratings

BenzingaDec 21, 2023 04:41 ET

Cantor Fitzgerald Reiterates Overweight on Catalyst Pharmaceuticals, Maintains $27 Price Target

BenzingaAug 22, 2023 09:39 ET

Catalyst Pharmaceuticals Analyst Ratings

BenzingaAug 22, 2023 09:38 ET

Catalyst Pharmaceuticals Analyst Ratings

BenzingaAug 11, 2023 07:58 ET

HC Wainwright & Co. Reiterates Buy on Catalyst Pharmaceuticals, Maintains $24 Price Target

BenzingaJul 21, 2023 06:18 ET

Catalyst Pharmaceuticals Analyst Ratings

BenzingaJul 21, 2023 06:18 ET

The Latest Analyst Ratings for Catalyst Pharmaceuticals

BenzingaJun 21, 2023 14:00 ET

Truist Securities Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $24

BenzingaJun 21, 2023 12:56 ET

Cantor Fitzgerald Reiterates Overweight on Catalyst Pharmaceuticals, Maintains $25 Price Target

BenzingaJun 21, 2023 09:59 ET

HC Wainwright & Co. Reiterates Buy on Catalyst Pharmaceuticals, Maintains $24 Price Target

BenzingaMar 20, 2023 07:56 ET